Please login to the form below

Not currently logged in
Email:
Password:

GVHD

This page shows the latest GVHD news and features for those working in and with pharma, biotech and healthcare.

CHMP delays decision on Kiadis’ GVHD immunotherapy

CHMP delays decision on Kiadis’ GVHD immunotherapy

ATIR101 aims to target this, more specifically Graft-versus-Host-Disease (GVHD) along with cancer relapse. ... The T-cells that would normally cause GVHD are depleted from the donor lymphocytes using Kiadis Pharma’s photodepletion technology,

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics